First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland
| Autor: | Bożena Cybulska-Stopa, Barbara Ziółkowska, Łukasz Galus, Tomasz Kubiatowski, Stanisław Kieszko, Karolina Piejko, Jacek Mackiewicz, Piotr Rutkowski, Anna Drosik-Kwaśniewska, Jacek Calik, Grażyna Kamińska-Winciorek, Marcin Ziętek, Anna M. Czarnecka, Renata Pacholczak-Madej, Paweł Rogala, Katarzyna Gajewska-Wicher, Rafał Suwiński, Janusz Rolski, Agata Sałek-Zań, Natasza Kempa-Kamińska |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Multivariate analysis Drug-Related Side Effects and Adverse Reactions medicine.medical_treatment Programmed Cell Death 1 Receptor Immunology Pembrolizumab Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Immunology and Allergy Medicine 030212 general & internal medicine Stage (cooking) Adverse effect Immune Checkpoint Inhibitors Melanoma Aged Retrospective Studies Aged 80 and over business.industry Immunotherapy Middle Aged Prognosis medicine.disease Progression-Free Survival Survival Rate Clinical trial Nivolumab Treatment Outcome 030220 oncology & carcinogenesis Female Poland business |
| Zdroj: | Immunotherapy. 13:297-307 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2020-0217 |
| Popis: | Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC–IV) melanoma treated with anti-PD-1 in first-line therapy. Results: Estimated median overall survival (OS) and progression-free survival (PFS) were 19.9 and 7.9 months, respectively. Multivariate analysis confirmed that ECOG 0, no brain metastases, normal lactate dehydrogenase level and occurrence of immune-related adverse events (irAEs) were statistically significantly associated with improved OS and PFS. Any irAE occurred in 24% of patients. Grade 3 or Grade 4 irAEs occurred in 6% of patients. Conclusion: Analysis revealed a slightly worse OS in real-world treatment in comparison to clinical trials (KEYNOTE-006 and CheckMate 066). Polish population treatment results are similar to other studies of real-world data. PFS and ORR are similar in our research and clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|